WHO Guidelines on Hand Hygiene in Health Care - Safe Care ...
WHO Guidelines on Hand Hygiene in Health Care - Safe Care ...
WHO Guidelines on Hand Hygiene in Health Care - Safe Care ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<str<strong>on</strong>g>WHO</str<strong>on</strong>g> GUIDELINES ON HAND HYGIENE IN HEALTH CARE<br />
<strong>in</strong> 1.0–1.2 litre bags for use <strong>in</strong> wall-mounted dispensers are<br />
the least expensive; pump bottles and small pocket-sized<br />
bottles are more expensive; and foam products that come<br />
<strong>in</strong> pressurized cans are the most expensive. Presumably,<br />
a locally-produced soluti<strong>on</strong> composed of <strong>on</strong>ly ethanol or<br />
isopropanol plus 1% or 2% glycerol would be less expensive<br />
than commercially produced formulati<strong>on</strong>s. Boyce estimated<br />
that a 450-bed community teach<strong>in</strong>g hospital <strong>in</strong> the USA spent<br />
US$ 22 000 (US$ 0.72 per patient-day) <strong>on</strong> 2% chlorhexid<strong>in</strong>ec<strong>on</strong>ta<strong>in</strong><strong>in</strong>g<br />
preparati<strong>on</strong>s, pla<strong>in</strong> soap, and an alcohol-based hand<br />
r<strong>in</strong>se. 1053 When hand hygiene supplies for cl<strong>in</strong>ics and n<strong>on</strong>-patient<br />
care areas were <strong>in</strong>cluded, the total annual budget for soaps<br />
and hand antiseptic agents was US$ 30 000 (about US$ 1 per<br />
patient-day).<br />
Annual hand hygiene product budgets at other <strong>in</strong>stituti<strong>on</strong>s vary<br />
c<strong>on</strong>siderably because of differences <strong>in</strong> usage patterns and<br />
vary<strong>in</strong>g product prices. Countries/states/regi<strong>on</strong>s/localities with<br />
centralized purchas<strong>in</strong>g can achieve ec<strong>on</strong>omies <strong>on</strong> a scale that<br />
can result <strong>in</strong> c<strong>on</strong>siderable cost reducti<strong>on</strong> of products. A recent<br />
cost comparis<strong>on</strong> of surgical scrubb<strong>in</strong>g with an antimicrobial<br />
soap versus brushless scrubb<strong>in</strong>g with an alcohol-based<br />
handrub revealed that costs and time required for pre-operative<br />
scrubb<strong>in</strong>g were less with the alcohol-based product. 328 In a trial<br />
c<strong>on</strong>ducted <strong>in</strong> two ICUs, Lars<strong>on</strong> and colleagues 329 found that the<br />
cost of us<strong>in</strong>g an alcohol-based handrub was half that of us<strong>in</strong>g<br />
an antimicrobial soap for handwash<strong>in</strong>g (US$ 0.025 vs US$<br />
0.05 per applicati<strong>on</strong>, respectively). In another study c<strong>on</strong>ducted<br />
<strong>in</strong> two ne<strong>on</strong>atal ICUs, <strong>in</strong>vestigators looked at the costs of a<br />
traditi<strong>on</strong>al handwash<strong>in</strong>g regimen us<strong>in</strong>g soap, use of an alcoholbased<br />
handrub supplemented by a n<strong>on</strong>-antimicrobial soap, use<br />
of hand loti<strong>on</strong>, and nurs<strong>in</strong>g time required for hand hygiene. 646<br />
Although product costs were higher when the alcohol-based<br />
handrub was used, the overall cost of hand hygiene was lower<br />
with the handrub because it required less nurs<strong>in</strong>g time.<br />
3.5 Typical cost-sav<strong>in</strong>gs from hand hygiene<br />
promoti<strong>on</strong> programmes<br />
To assess the cost sav<strong>in</strong>gs of hand hygiene promoti<strong>on</strong><br />
programmes, it is necessary to c<strong>on</strong>sider the potential sav<strong>in</strong>gs<br />
that can be achieved by reduc<strong>in</strong>g the <strong>in</strong>cidence of HCAIs. One<br />
of the easiest ways to assess the cost sav<strong>in</strong>gs is to estimate the<br />
excess hospital costs associated with the excess patient days<br />
caused by HCAIs. In a recent study by St<strong>on</strong>e and colleagues,<br />
costs of catheter-related bloodstream <strong>in</strong>fecti<strong>on</strong> (CR-BSI),<br />
surgical site <strong>in</strong>fecti<strong>on</strong> (SSI), ventilator-associated pneum<strong>on</strong>ia<br />
(VAP), and hip SSIs were estimated and found to be a m<strong>in</strong>imum<br />
of US$ 5500 per episode. The authors further reported that<br />
CR-BSI caused by MRSA may cost as much as US$ 38 000<br />
per episode. 1054 Table III.3.1 provides a summary of the costs<br />
of the four most comm<strong>on</strong> HCAIs based <strong>on</strong> a systematic review<br />
of literature published by St<strong>on</strong>e and colleagues for periods<br />
1990–2000 and 2001–2004. 15,1055<br />
In additi<strong>on</strong> to the costs reported above, there are several hidden<br />
costs that are not <strong>in</strong>cluded <strong>in</strong> the calculati<strong>on</strong> of these figures.<br />
These costs could <strong>in</strong>stead be referred to as lost “opportunities<br />
for sav<strong>in</strong>g”. St<strong>on</strong>e and colleagues provide several examples.<br />
An unscheduled revisit to the operat<strong>in</strong>g room for <strong>in</strong>cisi<strong>on</strong> and<br />
dra<strong>in</strong>age after an SSI can limit the number of procedures that<br />
can be performed <strong>in</strong> a day. Hold-ups often cause delays and<br />
postp<strong>on</strong>ement of scheduled procedures. Another example of a<br />
hidden cost <strong>in</strong>cludes the dissatisfacti<strong>on</strong> of the patient and the<br />
referr<strong>in</strong>g doctor. Research suggests that dissatisfied customers<br />
often have the tendency to tell more people about the<br />
deficiencies <strong>in</strong> their care. Hence, the loss of exist<strong>in</strong>g customers<br />
(patients) means higher replacement costs associated with<br />
attract<strong>in</strong>g and receiv<strong>in</strong>g new patients. These <strong>in</strong>clude costs for<br />
market<strong>in</strong>g and register<strong>in</strong>g new patients <strong>in</strong>to the medical records<br />
system and the costs of counter<strong>in</strong>g any negative publicity and<br />
build<strong>in</strong>g renewed trust.<br />
Thus, it is not surpris<strong>in</strong>g that the excess hospital costs<br />
associated with <strong>on</strong>ly four or five HCAIs of average severity may<br />
equal the entire annual budget for hand hygiene products used<br />
<strong>in</strong> <strong>in</strong>patient care areas. Just <strong>on</strong>e severe SSI, lower respiratory<br />
<strong>in</strong>fecti<strong>on</strong>, or BSI may cost the hospital more than the entire<br />
annual budget for antiseptic agents used for hand hygiene. 1053<br />
For example, <strong>in</strong> a study c<strong>on</strong>ducted <strong>in</strong> a Russian ne<strong>on</strong>atal ICU,<br />
the authors estimated that the excess cost of <strong>on</strong>e health careassociated<br />
BSI (US$ 1100) would cover 3265 patient-days of<br />
hand antiseptic use (US$ 0.34 per patient-day). 687 The authors<br />
estimated that the alcohol-based handrub would be cost sav<strong>in</strong>g<br />
if its use prevented approximately 3.5 BSIs per year or 8.5<br />
pneum<strong>on</strong>ias per year. In another study, it was estimated that<br />
cost sav<strong>in</strong>gs achieved by reduc<strong>in</strong>g the <strong>in</strong>cidence of C. difficileassociated<br />
disease and MRSA <strong>in</strong>fecti<strong>on</strong>s far exceeded the<br />
additi<strong>on</strong>al cost of us<strong>in</strong>g an alcohol-based handrub. 429<br />
Several studies provided some quantitative estimates of the<br />
cost sav<strong>in</strong>gs from hand hygiene promoti<strong>on</strong> programmes. 60,181<br />
Webster and colleagues 181 reported a cost sav<strong>in</strong>g of<br />
approximately US$ 17 000 result<strong>in</strong>g from the reduced use<br />
of vancomyc<strong>in</strong> follow<strong>in</strong>g the observed decrease <strong>in</strong> MRSA<br />
<strong>in</strong>cidence over a 7-m<strong>on</strong>th period. Similarly, MacD<strong>on</strong>ald and<br />
colleagues reported that the use of an alcohol-based hand gel<br />
comb<strong>in</strong>ed with educati<strong>on</strong> sessi<strong>on</strong>s and performance feedback<br />
to HCWs reduced the <strong>in</strong>cidence of MRSA <strong>in</strong>fecti<strong>on</strong>s and<br />
expenditures for teicoplan<strong>in</strong> (used to treat such <strong>in</strong>fecti<strong>on</strong>s). 489<br />
For every UK£ 1 spent <strong>on</strong> alcohol-based gel, UK£ 9–20 were<br />
saved <strong>on</strong> teicoplan<strong>in</strong> expenditure.<br />
Includ<strong>in</strong>g both direct costs associated with the <strong>in</strong>terventi<strong>on</strong><br />
(<strong>in</strong>creased use of handrub soluti<strong>on</strong>, poster reproducti<strong>on</strong>, and<br />
implementati<strong>on</strong>) and <strong>in</strong>direct costs associated with HCW time,<br />
Pittet and colleagues 60 estimated the costs of the programme<br />
to be less than US$ 57 000 per year for a 2600-bed hospital,<br />
an average of US$ 1.42 per patient admitted. Supplementary<br />
costs associated with the <strong>in</strong>creased use of alcohol-based<br />
handrub soluti<strong>on</strong> averaged US$ 6.07 per 100 patient-days.<br />
Based <strong>on</strong> c<strong>on</strong>servative estimates of US$ 100 saved per<br />
<strong>in</strong>fecti<strong>on</strong> averted, and assum<strong>in</strong>g that <strong>on</strong>ly 25% of the observed<br />
reducti<strong>on</strong> <strong>in</strong> the <strong>in</strong>fecti<strong>on</strong> rate has been associated with<br />
improved hand hygiene practice, the programme was largely<br />
cost effective. A subsequent follow-up study performed <strong>in</strong> the<br />
same <strong>in</strong>stituti<strong>on</strong> determ<strong>in</strong>ed the direct costs of the alcoholbased<br />
handrub used, other direct costs, <strong>in</strong>direct costs for<br />
hand hygiene promoti<strong>on</strong>, and the annual prevalence of HCAI<br />
for 1994–2001. 490 Total costs for the hand hygiene programme<br />
averaged Swiss francs (CHF) 131 988 between 1995 and<br />
2001, or about CHF 3.29 per admissi<strong>on</strong>. The prevalence of<br />
HCAI decreased from 16.9 per 100 admissi<strong>on</strong>s <strong>in</strong> 1994 to<br />
9.5 per 100 admissi<strong>on</strong>s <strong>in</strong> 2001. Total costs of HCAIs were<br />
estimated to be CHF 132.6 milli<strong>on</strong> for the entire study period.<br />
170